Cargando…

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas

Genetic sub-clonality has been described in multiple malignancies, however the presence of sub-clonality for major drivers in lung adenocarcinoma and its clinical significance is a subject under debate. Using molecular and morphometric approach, 347 lung adenocarcinoma samples were analyzed for KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Einav, Bick, Tova, Sarji, Shada, Shentzer, Talia, Prinz, Elad, Yehiam, Liza, Sabo, Edmond, Ben-Izhak, Ofer, Hershkovitz, Dov
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542222/ https://www.ncbi.nlm.nih.gov/pubmed/28501852 http://dx.doi.org/10.18632/oncotarget.17399

Ejemplares similares

Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection
por: Ostrow, Sheli L., et al.
Publicado: (2016)

Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA
por: Fahoum, Ibrahim, et al.
Publicado: (2018)

Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy
por: Asor, Eyal, et al.
Publicado: (2017)

Association between Nuclear Morphometry Parameters and Gleason Grade in Patients with Prostatic Cancer
por: Malshy, Kamil, et al.
Publicado: (2022)

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel
por: BAR-SELA, GIL, et al.
Publicado: (2013)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
por: Peleg Hasson, Shira, et al.
Publicado: (2022)

Discovering the drivers of clonal hematopoiesis
por: Pich, Oriol, et al.
Publicado: (2022)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Clonal Hematopoiesis and Vascular Disease
por: Amancherla, Kaushik, et al.
Publicado: (2022)

Clonal Architectures and Driver Mutations in Metastatic Melanomas
por: Ding, Li, et al.
Publicado: (2014)

Germline risk of clonal haematopoiesis
por: Silver, Alexander J., et al.
Publicado: (2021)

Expanding approaches to detect clonal hematopoiesis
por: Khan, M.A. Wasay, et al.
Publicado: (2021)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
por: Wu, Di, et al.
Publicado: (2020)

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
por: Muzumdar, Mandar Deepak, et al.
Publicado: (2016)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
por: Fleischman, Angela G.
Publicado: (2015)

Disturbance Is an Important Driver of Clonal Richness in Tropical Seagrasses
por: McMahon, Kathryn M., et al.
Publicado: (2017)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

P1076: PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS
por: Dann, Eldad, et al.
Publicado: (2023)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Artificial intelligence (AI) molecular analysis tool assists in rapid treatment decision in lung cancer: a case report
por: Waissengrin, Barliz, et al.
Publicado: (2023)

Clonal expansion in B-CLL: Fungal drivers or self-service?
por: Greaves, Mel
Publicado: (2013)

Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome
por: Baliakas, Panagiotis, et al.
Publicado: (2021)

Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes
por: Studd, James B., et al.
Publicado: (2021)

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

Wheatgrass Juice Administration and Immune Measures during Adjuvant Chemotherapy in Colon Cancer Patients: Preliminary Results
por: Avisar, Adva, et al.
Publicado: (2020)

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features
por: Jia, Xiaoli, et al.
Publicado: (2015)

肺腺癌EGFR与KRAS基因突变状态分析
Publicado: (2015)

Expression and role of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues
por: Lin, Xinsheng, et al.
Publicado: (2019)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

P527: DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA
por: Matsuo, Hidemasa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjbkc3dk87bt88li2i3romaomj